Physician profile
Mark A Holman
NPI 1972720613
$501.78
in general payments reported to CMS, 2019-2025
4 companies · $78.33 in 2025
The $78.33 reported for 2025 was more than what a typical Endodontics provider received nationally (typical 2025 total: $58.83).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $195 · 2020: $62.67 · 2022: $31.70 · 2024: $134 · 2025: $78.33.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $212.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $212.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimvie INC. | $243.71 | 2022-2025 | |
| Sonendo INC | $150.41 | 2019 | |
| Henry Schein, INC. | $62.67 | 2020 | |
| Zimmer Biomet Holdings, INC. | $44.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Holman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.